Loading data for NVCT — first visit, this takes a few seconds.

Preisalarm

Nuvectis Pharma Inc. (NVCT)

NasdaqCM: NVCT · Echtzeitkurs · USD

23.33

+2.42 (11.57%)

Zum Schluss: Aug 19, 2026, 8:00 PM

11.57% (1D)

Keine Daten verfügbar

Geld	n/a
Marktkapitalisierung	760.13 Mio
Umsatz (TTM)	n/a
Nettogewinn (TTM)	-30.27 Mio
Beta	-0.26
EPS (ttm)	-1.32
KGV (TTM)	n/a
Forward-KGV	-24.3
KBV (TTM)	68.62
KUV (TTM)	n/a
Earnings Date	Nov 3, 2026

Brief	n/a
Volumen	362,710
Ø Vol. (20D)	312,191
Eröffnung	21.44
Vortagesschluss	20.91
Tagesspanne	21.00 - 23.74
52-Wk Range	5.55 - 29.27
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über NVCT

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its na...

[Mehr lesen]

Branche Biotechnology

Sektor Healthcare

IPO Datum Feb 4, 2022

Mitarbeiter 16

Börse NasdaqCM

Tickersymbol NVCT

Website https://www.nuvectis.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Nuvectis Pharma 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -26.44 Mio, ein Anstieg von 39.17 %.

Finanzberichte

Gewinnüberraschung

Nuvectis Pharma hat die Quartalszahlen am Aug 4, 2026 veröffentlicht:

Umsatz von $0 verfehlt die Erwartungen um $0, mit NaN% Wachstum im Jahresvergleich.

EPS von -0.3 verfehlt die Erwartungen um -0.04, mit 0.00% Wachstum im Jahresvergleich.

Nächste Ergebnisveröffentlichung

Nuvectis Pharma Inc. wird voraussichtlich die Quartalszahlen veröffentlichen am Nov 3, 2026, vor Börseneröffnung.
Analysten erwarten einen Umsatz von ... Upgrade

Nachrichten

vor 3 Wochen · Zacks

Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know

The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 56.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...

vor 1 Monat · Zacks

Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

The consensus price target hints at a 61.5% upside potential for Nuvectis Pharma (NVCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings e...

vor 1 Monat · Zacks

What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?

Does Nuvectis Pharma, Inc. (NVCT) have what it takes to be a top stock pick for momentum investors? Let's find out.

vor 1 Monat · InvestorsHub

Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT)

Secondary offering priced well below previous closeNuvectis Pharma (NASDAQ:NVCT) shares dropped 25% in premarket trading on Tuesday after the clinical-stage biopharmaceutical company priced a $100 mil...

vor 1 Monat · Zacks

What Makes Nuvectis Pharma (NVCT) a New Buy Stock

Nuvectis Pharma (NVCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seite 1 von 2

Nuvectis Pharma Inc. (NVCT)